Ruichen Li1, Shu Tian1, Lan Lin2, Quan Liu3, Shengzi Wang4. 1. Department of Radiation Oncology, Eye, Ear, Nose and Throat Hospital of Fudan University, 83 Fenyang Road, Xuhui, Shanghai, 200031, People's Republic of China. 2. Department of Pathology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, 200031, People's Republic of China. 3. Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, 200031, People's Republic of China. 4. Department of Radiation Oncology, Eye, Ear, Nose and Throat Hospital of Fudan University, 83 Fenyang Road, Xuhui, Shanghai, 200031, People's Republic of China. shengziwang@fudan.edu.cn.
Abstract
PURPOSE: Definitive radiotherapy (RT) is recommended by NCCN guidelines for T4b tumors of sinonasal squamous cell carcinomas (SNSCC). However, no multi-institutional clinical studies have proved its advantage over surgery-based modalities. The aim of this study was to assess the survival of T4bN0M0 SNSCC patients who received surgery plus postoperative radiation (S + PORT) compared with those who received RT. METHODS: This study extracted 220 patients from the SEER database from 2004 to 2015. Propensity score matching (PSM) was used to eliminate the baseline variations. RESULTS: In SEER database, 43.6% of patients received S + PORT, and subsequently followed by RT (36.4%). Five-year overall survival (OS) and cancer-specific survival rates (CSS) in S + PORT were 42.5% and 46.9%, respectively, significantly better than for RT (21.7% and 26.7%). Multivariate analysis showed that therapy of RT had higher cancer-specific mortality risk than S + PORT [hazard ratio (HR) 1.578, p = 0.032]. After PSM, 57 pairs of patients were selected. There was still a significant difference noted with regard to 5-year OS or 5-year CSS between patients receiving S + PORT and RT (43% vs 22.5%, p = 0.012; 45.8% vs 27.7%, p = 0.025). The univariate and multivariate analyses of factors predictive of CSS showed that therapy of RT (HR 1.877, p = 0.018) and primary subsite of maxillary sinus (HR 2.629, p = 0.001) were significantly correlated with adverse outcomes. CONCLUSION: Combination of surgery and postoperative radiotherapy may contribute to prolonged survival in T4bN0M0 SNSCC. Invasion of the sites of T4b tumors is not an absolute contraindication for surgery.
PURPOSE: Definitive radiotherapy (RT) is recommended by NCCN guidelines for T4b tumors of sinonasal squamous cell carcinomas (SNSCC). However, no multi-institutional clinical studies have proved its advantage over surgery-based modalities. The aim of this study was to assess the survival of T4bN0M0 SNSCC patients who received surgery plus postoperative radiation (S + PORT) compared with those who received RT. METHODS: This study extracted 220 patients from the SEER database from 2004 to 2015. Propensity score matching (PSM) was used to eliminate the baseline variations. RESULTS: In SEER database, 43.6% of patients received S + PORT, and subsequently followed by RT (36.4%). Five-year overall survival (OS) and cancer-specific survival rates (CSS) in S + PORT were 42.5% and 46.9%, respectively, significantly better than for RT (21.7% and 26.7%). Multivariate analysis showed that therapy of RT had higher cancer-specific mortality risk than S + PORT [hazard ratio (HR) 1.578, p = 0.032]. After PSM, 57 pairs of patients were selected. There was still a significant difference noted with regard to 5-year OS or 5-year CSS between patients receiving S + PORT and RT (43% vs 22.5%, p = 0.012; 45.8% vs 27.7%, p = 0.025). The univariate and multivariate analyses of factors predictive of CSS showed that therapy of RT (HR 1.877, p = 0.018) and primary subsite of maxillary sinus (HR 2.629, p = 0.001) were significantly correlated with adverse outcomes. CONCLUSION: Combination of surgery and postoperative radiotherapy may contribute to prolonged survival in T4bN0M0 SNSCC. Invasion of the sites of T4b tumors is not an absolute contraindication for surgery.
Authors: Tyler P Robin; Bernard L Jones; Oren M Gordon; Andy Phan; Diana Abbott; Jessica D McDermott; Julie A Goddard; David Raben; Ryan M Lanning; Sana D Karam Journal: Cancer Date: 2017-04-03 Impact factor: 6.860
Authors: J Michel; N Fakhry; J Mancini; D Braustein; E Moreddu; A Giovanni; P Dessi Journal: Int J Oral Maxillofac Surg Date: 2013-08-17 Impact factor: 2.789
Authors: Carl H Snyderman; Ricardo L Carrau; Amin B Kassam; Adam Zanation; Daniel Prevedello; Paul Gardner; Arlan Mintz Journal: J Surg Oncol Date: 2008-06-15 Impact factor: 3.454
Authors: Bradford S Hoppe; Carl J Nelson; Daniel R Gomez; Lauren D Stegman; Abraham J Wu; Suzanne L Wolden; David G Pfister; Michael J Zelefsky; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-18 Impact factor: 7.038
Authors: Ahmed A Keerio; Muhammad U Qayyum; Alina Kashif; Rahim Dhanani; Asma Rashid; Muhammad Faisal; Raza Hussain; Arif Jamshed Journal: Cureus Date: 2022-06-03